2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Marijuana Abuse
3
Neoplasms
2
Epilepsy
2
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Pancreatic Cancer Non-resectable
1
Pain
1
Opioid-Related Disorders
1
Neurodevelopmental Disorders
1
Multiple Sclerosis
1
Marijuana Use
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
Carcinoma, Hepatocellular
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Interventions
Ribavirin
5
ledipasvir, sofosbuvir drug combination
3
sofosbuvir-velpatasvir drug combination
2
elbasvir-grazoprevir drug combination
2
Sorafenib
2
Sofosbuvir
2
Chromatography, High Pressure Liquid
2
tremelimumab
1
telaprevir
1
rocakinogene sifuplasmid
1
pembrolizumab
1
peginterferon alfa-2a
1
navitoclax
1
menatetrenone
1
ledipasvir
1
hepatitis C immune globulin, human
1
grazoprevir
1
elbasvir
1
Rapid Diagnostic Tests
1
Raltegravir Potassium
1
Patient Navigation
1
Medical Marijuana
1
Mass Screening
1
Introns
1
Infliximab
1
Immunoglobulin G
1
Immunoenzyme Techniques
1
Hypothermia, Induced
1
Enzyme-Linked Immunosorbent Assay
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hepatitis C
×
Medical Marijuana
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled